Skip to main content

Fairchem Organics Ltd

NSE: FAIRCHEMOR BSE: 543252

Fairchem Organics Limited was established in 2019, wherein Fairchem Speciality Limited (FSL) transferred the businesses of Oleo chemicals and nutraceuticals as per the scheme of demerger. Fairchem Organics is engaged in manufacturing of specialty chemicals like dimer acid, linoleic acid, mixed tocopherol concentrate and sterols concentrate, which find application in various industries like nutraceuticals, paints, printing ink, detergents, adhesives, etc.[1]

615
52W: ₹428 — ₹1103
PE 129 · Book ₹202 · +204% vs book
Market Cap₹801 Cr
Stock P/E129Price to Earnings
ROCE3.34%Return on Capital
ROE2.2%Return on Equity
Div. Yield1.21%Face Value ₹10

Strengths

  • +Promoter holding has increased by 2.07% over last quarter.

Weaknesses

  • Stock is trading at 2.98 times its book value
  • The company has delivered a poor sales growth of 3.00% over past five years.
  • Company has a low return on equity of 8.08% over last 3 years.
  • Company might be capitalizing the interest cost

Shareholding Pattern

Promoters63.25%
FIIs6.35%
DIIs3.99%
Public26.4%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters58.71%58.71%61.2%2.561.2%61.2%61.2%61.2%63.25%2.0
FIIs6.29%6.36%0.16.31%0.16.31%6.28%0.06.18%0.16.34%0.26.35%0.0
DIIs5.16%5.16%5.16%5.69%0.55.77%0.15.77%5.42%0.33.99%1.4
Public29.84%29.79%0.127.33%2.526.8%0.526.76%0.026.86%0.127.05%0.226.4%0.7

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales148.11160.56164.93138.62113.57120.78131.06111.52100.13116.93
Expenses128.36141.79143.16129.86105.74116.36125.83107.3395.96108.9
Operating Profit19.7518.7721.778.767.834.425.234.194.178.03
OPM %13.33%11.69%13.2%6.32%6.89%3.66%3.99%3.76%4.16%6.87%
Net Profit12.3311.7613.854.013.520.591.170.77-0.13.69
EPS ₹9.479.0310.643.082.70.450.90.59-0.082.83

AI Insights

Revenue Trend

Mar 2026 revenue at ₹460Cr, down 14.5% YoY. OPM at 5%.

Debt Position

Borrowings at ₹84Cr. Debt-to-equity ratio: 0.34x. Healthy balance sheet.

Capex Cycle

CWIP at ₹18Cr (9% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 3.99% (-1.24pp change). FIIs: 6.35% (+0.11pp change). Promoters hold 63.25%.

Margin & Efficiency

ROCE improving from 0% (Mar 2020) to 3% (Mar 2026). Working capital days: 53.

Valuation

PE 129x with 3.34% ROCE. Price is 204% above book value of ₹202. Dividend yield: 1.21%.

Recent Announcements